SpringWorks Therapeutics Q2 2020 Earnings Report
Key Takeaways
SpringWorks Therapeutics reported a net loss of $19.9 million for the second quarter of 2020. The company completed enrollment in the Phase 3 DeFi trial of nirogacestat and initiated a Phase 1 trial evaluating nirogacestat in combination with a BCMA therapy. SpringWorks had $291.2 million in cash, cash equivalents, and marketable securities as of June 30, 2020.
Completed enrollment in Phase 3 DeFi trial of nirogacestat for desmoid tumors.
Dosed first patient in Phase 1b trial of nirogacestat with BLENREP for multiple myeloma.
Received a new patent for the treatment of desmoid tumors with nirogacestat.
Cash, cash equivalents and marketable securities were $291.2 million as of June 30, 2020.
SpringWorks Therapeutics
SpringWorks Therapeutics
Forward Guidance
The company will remain focused on executing against its objectives and believes it is well-positioned to progress its pipeline across its three distinct oncology focus areas of late-stage rare oncology, BCMA combinations in multiple myeloma and biomarker-defined metastatic solid tumors.